Study S001102

Intensive Exenatide Therapy in Hyperglycemic Patients Admitted to the Coronary Intensive Care Unit

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT00736229
Study type: INTERVENTIONAL
Phase: PHASE4
Masking: NONE
Status: COMPLETED
Enrollment: 40
Start: 2008-08
Primary completion: 2011-06
Lead sponsor: Saint Luke's Health System
Conditions: Hyperglycemia; Acute Coronary Syndromes; Myocardial Infarction
Interventions: DRUG:Exenatide
Results posted: TRUE

Registered primary outcomes

Median Glucose Values From Steady State Through 48 Hours or Until Discharge. [1-48 hours]
Time to Steady State [Start of infusion through 48 hours or until discharge]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0026373	Management of hyperglycemia with the administration of intravenous exenatide to patients in the cardiac intensive care unit. Abuannadi M, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists	2013	Other trial	PMID 23186969 DOI	registry reference RESULT:23186969
R0047777	IV Exenatide Has the Same Efficacy as Insulin in C ICU Patients, without Inducing Hypoglycemia Robert E. Buckley, MD Conference Express	2011	Other	DOI	cites ClinicalTrials.gov:NCT00736229